Specialized Therapies | HIV and Oncology
Press Releases and Company Announcements
Theratechnologies to Present Preclinical Data at AACR Demonstrating Synergy Between TH1902 and Anti-PD-L1 Immunotherapy in Cold Tumor Model
Theratechnologies Reports Financial Results and Business Updates for the Fourth Quarter and Full Year Fiscal 2022
Theratechnologies Announces Amendment to its Term Loan Facility With Affiliates of Marathon Asset Management
Pipeline & Medicines
Product Pipeline & Portfolio
Theratechnologies develops and commercializes innovative therapies. The Company currently commercializes two products in the field of HIV. Trogarzo® and EGRIFTA SV® are approved in the United States. We have a Phase 1 clinical trial in oncology using our novel and proprietary SORT1+ Technology™. We also plan to initiate a Phase 3 clinical trial to evaluate tesamorelin as a potential treatment for nonalcoholic steatohepatitis (NASH), a severe liver condition which affects a growing number of people around the world.
Our Commercialized Products
Making a difference through innovation
Theratechnologies makes a difference in the lives of patients through the development and commercialization of products addressing important unmet medical needs.